Medori R, Tritschler H J, LeBlanc A, Villare F, Manetto V, Chen H Y, Xue R, Leal S, Montagna P, Cortelli P
Division of Neuropathology, Case Western Reserve University, Cleveland, OH 44106.
N Engl J Med. 1992 Feb 13;326(7):444-9. doi: 10.1056/NEJM199202133260704.
We previously described two members of a family affected by an apparently genetically determined fatal disease characterized clinically by progressive insomnia, dysautonomia, and motor signs and characterized pathologically by severe atrophy of the anterior ventral and mediodorsal thalamic nuclei. Five other family members who died of this disease, which we termed "fatal familial insomnia," had broader neuropathologic changes suggesting that fatal familial insomnia could be a prion disease.
We used antibodies to prion protein (PrP) to perform dot and Western blot analyses, with and without proteinase K, on brain tissue obtained at autopsy from two patients with fatal familial insomnia, three patients with sporadic Creutzfeldt-Jakob disease, and six control subjects. The coding region of the PrP gene was amplified and sequenced in the samples from the two patients with fatal familial insomnia. Restriction-enzyme analysis was carried out with amplified PrP DNA from 33 members of the kindred.
Protease-resistant PrP was found in both patients with fatal familial insomnia, but the size and number of protease-resistant fragments differed from those in Creutzfeldt-Jakob disease. In the family with fatal familial insomnia, all 4 affected members and 11 of the 29 unaffected members had a point mutation in PrP codon 178 that results in the substitution of asparagine for aspartic acid and elimination of the Tth111 I restriction site. Linkage analysis showed a close relation between the point mutation and the disease (maximal lod score, 3.4 when theta was zero).
Fatal familial insomnia is a prion disease with a mutation in codon 178 of the PrP gene, but the disease phenotype seems to differ from that of previously described kindreds with the same point mutation.
我们之前描述了一个受一种明显由基因决定的致命疾病影响的家族中的两名成员。该疾病临床上以进行性失眠、自主神经功能障碍和运动体征为特征,病理上以前腹侧和丘脑背内侧核的严重萎缩为特征。死于这种我们称为“致命性家族性失眠症”疾病的另外五名家族成员有更广泛的神经病理变化,提示致命性家族性失眠症可能是一种朊病毒病。
我们使用针对朊病毒蛋白(PrP)的抗体,对两名致命性家族性失眠症患者、三名散发性克雅氏病患者以及六名对照者尸检获得的脑组织进行了有无蛋白酶K的斑点印迹和蛋白质印迹分析。对两名致命性家族性失眠症患者的样本中PrP基因的编码区进行了扩增和测序。对来自该家族33名成员的扩增PrP DNA进行了限制性酶切分析。
在两名致命性家族性失眠症患者中均发现了蛋白酶抗性PrP,但蛋白酶抗性片段的大小和数量与克雅氏病中的不同。在患有致命性家族性失眠症的家族中,所有4名患病成员和29名未患病成员中的11名在PrP密码子178处有一个点突变,该突变导致天冬酰胺取代天冬氨酸并消除了Tth111 I限制性酶切位点。连锁分析显示该点突变与疾病之间存在密切关系(当θ为零时,最大优势对数分数为3.4)。
致命性家族性失眠症是一种PrP基因密码子178发生突变的朊病毒病,但该疾病表型似乎与先前描述的具有相同点突变的家族不同。